(RTTNews) – We are hardly two weeks into 2021, and shares of Relmada Therapeutics Inc. (RLMD) have gained 22% so far this year.

Relmada is a late-stage biotech company developing drugs to treat diseases of the central nervous system in an entirely new way. The lead drug candidate is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that…

All your Asset management needs with Global Asset Management Seoul Korea Magazine

This post was originally published on this site


Comments are closed.